TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03176563

Intervention type: DRUG
Intervention: Arctuvan
Description: application of a herbal drug in the clinical trial REGATTA (NCT03151603)

Intervention type: DRUG
Intervention: Placebo to Fosfomycin
Description: application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)

Intervention type: DRUG
Intervention: Fosfomycin
Description: application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)

Intervention type: DRUG
Intervention: Placebo to Arctuvan
Description: application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
Study: NCT02818920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications
Study: NCT04760886

Intervention type: OTHER
Intervention: Type of hospital (rural DGH vs Urban MTC)
Description: In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.

Intervention type: OTHER
Intervention: Type of hospital (rural DGH vs Urban MTC)
Description: In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
Study: NCT03435016

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic work-up
Description: Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
Study: NCT00445068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT04079166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCIB1 or iSCIB1+ DNA vaccine
Description: Participants receive up to 10 doses of either SCIB1 or iSCIB1+ up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab.~Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 or iSCIB1+ and given as per standard treatment.
Study: NCT00523120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: topical solution used in ear 5 drops 8 3/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexotc
Description: aural drops
Study: NCT05179642

Intervention type: OTHER
Intervention: OPTIM-EHPAD tool
Description: This is a randomized, cluster stepped wedge study. Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents.
Study: NCT00411281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given subcutaneously

Intervention type: PROCEDURE
Group type: OTHER
Intervention: observation
Description: No intervention
Study: NCT04711668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intraoperative ketamine bolus and infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: intraoperative lidocain bolus and infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intraoperative saline bolus and infusion
Study: NCT00640484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmoterol (CHF 4226)
Description: carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)
Study: NCT04631796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lehfilcon A contact lenses
Description: Silicone hydrogel contact lenses with investigational coating

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multipurpose disinfection solution
Description: Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
Study: NCT03118037

Intervention type: DEVICE
Intervention: Sonata System
Description: Transcervical access for radiofrequency ablation of uterine fibroids
Study: NCT03546335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-CZP
Description: 89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-CZP
Description: 89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-CZP
Description: 89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-CZP
Description: 89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
Study: NCT04104321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid
Description: Aramchol 300 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID
Study: NCT05189769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP no REACT
Description: Coping Power no REACT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP+/No REACT
Description: CP+ and no REACT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP and REACT
Description: Coping Power traditional and REACT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CP+ and REACT
Description: CP+ and REACT
Study: NCT01171352

Intervention type: PROCEDURE
Intervention: Transpulmonary Thermodilution
Description: A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
Study: NCT04184960

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastroscopy and gastric biopsies
Description: Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastroscopy and gastric biopsies
Description: Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM
Study: NCT02087748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% diclofenac sodium gel
Description: Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel 4gm applied topically Q6 hour for 48 hours
Study: NCT00955487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Description: iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen (placebo)
Description: Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
Study: NCT01310803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VALSTAR - Maintenance Therapy
Description: Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase

Intervention type: OTHER
Group type: OTHER
Intervention: No Maintenance treatment ( Standard of Care)
Description: Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
Study: NCT00584168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
Study: NCT03047551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal sonography
Description: Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal sonography
Description: Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
Study: NCT01641211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meducation device technique video
Description: 2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition video
Description: Children in this group will watch a 2-minute nutrition video.
Study: NCT02462928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar Pegol
Description: Abicipar pegol intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar Pegol
Description: Abicipar pegol intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab intravitreal injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham injection.
Study: NCT01135680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HPN-100
Description: single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HPN-100 or Placebo
Description: single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: single oral 400-mg dose on study Day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HPN-100
Description: single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HPN-100
Description: single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
Study: NCT02640820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensitizing DPCP Ointment
Description: Sensitization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment DPCP Ointment
Description: Treatment
Study: NCT00643669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-3789 Sterile Suspension
Description: Single administration by anterior juxtascleral depot
Study: NCT00146328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study: NCT01556035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
Study: NCT04536584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Coaching (Arm A)
Description: Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive approach (Arm B)
Description: Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
Study: NCT03434353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir Soproxil
Description: Administered orally once daily one hour before or one hour after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir Soproxil
Description: Administered orally once daily one hour before or one hour after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir Soproxil
Description: Administered orally once daily one hour before or one hour after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir Soproxil
Description: Administered orally once daily one hour before or one hour after a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Administered orally once daily with food
Study: NCT03739762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-STAND
Description: Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions. (As of 3/31/2022 Re-randomizations are no longer taking place)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living control
Description: In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
Study: NCT04144751

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood drawn at enrollment.
Study: NCT04431050

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care testing of respiratory viruses.
Description: Single use point of care diagnostic device.
Study: NCT00148954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VITALITY 2 Implantable Cardioverter Defibrillator
Description: VITALITY 2 ICD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Implantable Cardioverter Defibrillator
Description: Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
Study: NCT04058379

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: 3 ct scans : D0, D1 and D3
Study: NCT04292002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test@Work
Description: Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
Study: NCT00707850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
Study: NCT04469166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet
Description: Use of tourniquet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No tourniquet
Description: No use of tourniquet
Study: NCT02597803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Study: NCT02581293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1: Only visceral peritoneum will be closed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2 : Only parietal peritoneum will be closed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 3 : Both of them will be closed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 4: None of them will be closed
Study: NCT04426955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Concurrent Radiation

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation
Description: Concurrent Radiation
Study: NCT04849182

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vertistop D
Description: Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vertistop L
Description: Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)
Study: NCT02679950

Intervention type: GENETIC
Intervention: Next generation genome sequencing
Description: DNA will be extracted from each sample and assayed.

Intervention type: GENETIC
Intervention: Next generation genome sequencing
Description: DNA will be extracted from each sample and assayed.
Study: NCT02718599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terlipressin
Description: Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Study: NCT02125305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT02507622

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study: NCT01956825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: slim water